Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RET-positive Thyroid Cancer”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Testing effectiveness (Phase 2)Ended earlyNCT03131206
What this trial is testing

Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Who this might be right for
ALK-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Thyroid Cancer
Dana-Farber Cancer Institute 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT03157128
What this trial is testing

Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

Who this might be right for
Non-Small Cell Lung CancerMedullary Thyroid CancerColon Cancer+1 more
Eli Lilly and Company 857
Not applicableStudy completedNCT01945762
What this trial is testing

Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer

Who this might be right for
Symptomatic, Aggressive, Sporadic, Unresectable, LocallyAdvanced/Metastatic Medullary Thyroid Cancer (MTC)
Genzyme, a Sanofi Company 31
Testing effectiveness (Phase 2)Study completedNCT03037385
What this trial is testing

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Who this might be right for
RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+37 more
Hoffmann-La Roche 590
Testing effectiveness (Phase 2)Active Not RecruitingNCT04280081
What this trial is testing

Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

Who this might be right for
Solid TumorMedullary Thyroid Cancer
Eli Lilly and Company 77
Early research (Phase 1)Study completedNCT05241834
What this trial is testing

LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

Who this might be right for
Carcinoma, Non-Small-Cell LungThyroid Neoplasms
Eli Lilly and Company 70
Post-approval studies (Phase 4)Looking for participantsNCT07704658
What this trial is testing

Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)Thyroid CancerSolid Tumor Malignancies+1 more
Rigel Pharmaceuticals 12
Testing effectiveness (Phase 2)Looking for participantsNCT05668962
What this trial is testing

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Who this might be right for
Thyroid CancerThyroid CarcinomaMetastatic Thyroid Cancer+3 more
Massachusetts General Hospital 30
Testing effectiveness (Phase 2)Ended earlyNCT01838642
What this trial is testing

Ponatinib for Advanced Medullary Thyroid Cancer

Who this might be right for
Thyroid Neoplasms
National Institutes of Health Clinical Center (CC) 3
Testing effectiveness (Phase 2)UnknownNCT05278364
What this trial is testing

Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor

Who this might be right for
Non-Small Cell Lung CancerMedullary Thyroid CancerSolid Tumor
Shouyao Holdings (Beijing) Co. LTD 184